Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig plus docetaxel vs docetaxel in metastatic castration-resistant prostate cancer
CTR20255206Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20255206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255206.